Immatics Biotechnologies Capital Lease Obligations Over Time
IMTXW Stock | USD 0.41 0.01 2.38% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Immatics Biotechnologies Performance and Immatics Biotechnologies Correlation. Immatics |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immatics Biotechnologies. If investors know Immatics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immatics Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Revenue Per Share 0.766 | Quarterly Revenue Growth (0.16) | Return On Assets (0.12) | Return On Equity (0.24) |
The market value of Immatics Biotechnologies is measured differently than its book value, which is the value of Immatics that is recorded on the company's balance sheet. Investors also form their own opinion of Immatics Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Immatics Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immatics Biotechnologies' market value can be influenced by many factors that don't directly affect Immatics Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immatics Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immatics Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immatics Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Capital Lease Obligations Analysis
Compare Immatics Biotechnologies and related stocks such as Eliem Therapeutics, Scpharmaceuticals, and Milestone Pharmaceuticals Capital Lease Obligations Over Time
Select Fundamental2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SCPH | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.7 M | 1.4 M | 940 K | 476 K | 574 K | 1.5 M | 963.3 K |
MIST | 514 K | 514 K | 514 K | 514 K | 514 K | 514 K | 514 K | 514 K | 514 K | 514 K | 941 K | 698 K | 2.5 M | 2 M | 1.5 M |
MCRB | 9 M | 9 M | 9 M | 9 M | 9 M | 9 M | 9 M | 9 M | 7.2 M | 20.1 M | 15.7 M | 24.6 M | 111.5 M | 112.4 M | 118 M |
LUMO | 94 K | 94 K | 38 K | 46 K | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 319 K | 557 K | 233 K | 585 K | 419.9 K |
Immatics Biotechnologies and related stocks such as Eliem Therapeutics, Scpharmaceuticals, and Milestone Pharmaceuticals Capital Lease Obligations description
Immatics Biotechnologies capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to Immatics Biotechnologies asset purchases. For example, Immatics Biotechnologies can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as Immatics Biotechnologies control over an asset for a big portion of its life. The total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee.My Equities
My Current Equities and Potential Positions
immatics biotechnologies GmbH | IMTXW |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Location | Germany |
Exchange | NASDAQ Exchange |
USD 0.41
Additional Tools for Immatics Stock Analysis
When running Immatics Biotechnologies' price analysis, check to measure Immatics Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics Biotechnologies is operating at the current time. Most of Immatics Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Immatics Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics Biotechnologies' price. Additionally, you may evaluate how the addition of Immatics Biotechnologies to your portfolios can decrease your overall portfolio volatility.